ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATYR ATYR PHARMA INC

Market Closed 12-05 16:00:00 EST

0.8239

-0.0039

-0.47%

盘后0.8200

-0.0039-0.47%

19:58 EST

High0.8499	Low0.8100	Vol1.48M
Open0.8293	D1 Closing0.8278	Amplitude4.82%
Mkt Cap80.73M	Tradable Cap79.07M	Total Shares97.99M
T/O1.23M	T/O Rate1.55%	Tradable Shares95.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.8239,"timestamp":1764968400000,"preClose":0.8278,"halted":0,"volume":1483938,"hourTrading":{"tag":"盘后","latestPrice":0.82,"preClose":0.8239,"latestTime":"19:58 EST","volume":42680,"amount":35051.794609,"timestamp":1764982733517},"delay":0,"floatShares":95966000,"shares":97986634,"eps":-0.842499,"marketStatus":"Market Closed","change":-0.0039,"latestTime":"12-05 16:00:00 EST","open":0.8293,"high":0.8499,"low":0.81,"amount":1231523.5592574,"amplitude":0.0482,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.842499,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.8278,"preHourTrading":{"tag":"盘前","latestPrice":0.8201,"preClose":0.8278,"latestTime":"09:22 EST","volume":11811,"amount":9726.63204276,"timestamp":1764944524374},"postHourTrading":{"tag":"盘后","latestPrice":0.82,"preClose":0.8239,"latestTime":"19:58 EST","volume":42680,"amount":35051.794609,"timestamp":1764982733517},"volumeRatio":0.6620942922678775,"impliedVol":2.346,"impliedVolPercentile":0.756},"requestUrl":"/m/hq/s/ATYR/tweets","defaultTab":"tweets","newsList":[{"id":"2589170838","title":"aTyr Pharma Faces Nasdaq Delisting Risk Over Sub-$1 Stock Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2589170838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589170838?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:06","pubTimestamp":1764968802,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. has received a deficiency notice from the Nasdaq Stock Market, indicating that its common stock has closed below the $1.00 minimum bid price requirement for 30 consecutive business days, as mandated by Nasdaq Listing Rule 5550. The company has 180 calendar days, until June 2, 2026, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for 10 consecutive business days. If aTyr Pharma does not meet this requirement, it may be eligible for an additional 180-day compliance period, provided it satisfies other listing standards. Failure to regain compliance could result in the company's stock being delisted from the Nasdaq Capital Market. The company is actively monitoring the situation and evaluating options to address the deficiency.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8VQzMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2589889291","title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2589889291","media":"Reuters","labels":["policyRegulatory","dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589889291?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:42","pubTimestamp":1764938539,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL5b24Sz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","news_tag":"policyRegulatory,dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2588046898","title":"aTyr Pharma Faces Investor Class Action After Drug Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046898","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046898?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:39","pubTimestamp":1764765553,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements and concealed material adverse information regarding the efficacy of its drug candidate, Efzofitimod, particularly its ability to enable patients to taper off steroid usage. The situation came to light on September 15, 2025, when the company announced that its EFZO-FIT study did not meet its primary endpoint. Following this announcement, the company's stock price dropped sharply from $6.03 to $1.02 per share, representing an 83.2% decline in a single day. The legal action seeks to recover losses for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLbdxwTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2588108058","title":"aTyr Pharma Reveals EFZO-FIT Study Missed Primary Endpoint in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2588108058","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588108058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:39","pubTimestamp":1764679156,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL4LwsL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2586787834","title":"aTyr Pharma Faces Investor Lawsuit After Drug Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2586787834","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586787834?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:42","pubTimestamp":1764074533,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024 and September 12, 2025. The complaint alleges that the company made overly positive statements and concealed adverse information about the efficacy of its drug Efzofitimod, particularly regarding its ability to allow patients to fully taper steroid use. The litigation follows an investor call on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to the stock price plummeting from $6.03 to $1.02 per share in a single day. The case is being handled by Levi & Korsinsky, a law firm specializing in securities litigation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6cHSxK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2585148455","title":"aTyr Pharma Reveals Efzofitimod Trial Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2585148455","media":"Reuters","labels":["policyRegulatory","dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585148455?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:42","pubTimestamp":1763728942,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL99J8b1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Reveals Efzofitimod Trial Failure in Investor Call","news_tag":"policyRegulatory,dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2584867949","title":"aTyr Pharma Faces Class Action After Stock Plummets on Failed Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584867949","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584867949?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:44","pubTimestamp":1763556257,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024 and September 12, 2025. The lawsuit claims that the company issued positive statements about the efficacy of its drug, Efzofitimod, while concealing material adverse facts about its ability to allow patients to completely taper steroid usage. The truth was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a sharp decline in the company's stock price from $6.03 to $1.02 per share. The legal action seeks to recover damages for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDLccFkFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2584556608","title":"aTyr Pharma Faces Investor Class Action Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2584556608","media":"Reuters","labels":["shareholding","policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584556608?lang=en_us&edition=fundamental","pubTime":"2025-11-18 07:30","pubTimestamp":1763422215,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The legal action claims that the company misled shareholders, resulting in financial losses. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing investors in complex securities litigation and recovering significant sums for affected shareholders. Investors who experienced losses during the specified period are encouraged to seek more information about their potential eligibility in the lawsuit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate thi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL99x9N7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"aTyr Pharma Faces Investor Class Action Over Alleged Securities Fraud","news_tag":"shareholding,policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2584625803","title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625803","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625803?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:00","pubTimestamp":1763384430,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL2jGdxg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2583505010","title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2583505010","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583505010?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:50","pubTimestamp":1763124618,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL5l4M05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2583414548","title":"aTyr Pharma Faces Investor Class Action Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2583414548","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583414548?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:45","pubTimestamp":1763073915,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024 and September 12, 2025. The litigation claims that the company may have misled investors, prompting financial losses during this period. Levi & Korsinsky, a law firm specializing in securities litigation, is representing affected shareholders and encourages those impacted to seek more information about the case.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2DzGtj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"aTyr Pharma Faces Investor Class Action Over Securities Fraud Allegations","news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2582443879","title":"aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2582443879","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582443879?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:02","pubTimestamp":1762779755,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York, NY. President and CEO Sanjay S. Shukla will participate in a fireside chat, and company management will be available for one-on-one meetings with investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL53g3Tx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4139","LU0314104364.USD","NDAQ","ATYR","PIPR","IE00B64PRP62.GBP","BK4127","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","BK4588","LU2095319765.USD","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2581366898","title":"aTyr Pharma Is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581366898","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581366898?lang=en_us&edition=fundamental","pubTime":"2025-11-08 03:47","pubTimestamp":1762544820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 14:47 ET (19:47 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139","LU1267930573.SGD","LU0128525929.USD","LU0708994859.HKD","LU0310800379.SGD","BK4207","LU0029864427.USD"],"gpt_icon":0},{"id":"2581000287","title":"RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000287?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:37","pubTimestamp":1762519049,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on aTyr Pharma, with a price target of $1.00. The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-atyr-pharma-atyr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-atyr-pharma-atyr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR"],"gpt_icon":0},{"id":"2581463200","title":"aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581463200","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581463200?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:00","pubTimestamp":1762466444,"startTime":"0","endTime":"0","summary":"aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48706203/atyr-pharma-q3-eps-0-26-misses-0-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2581045415","title":"aTyr Pharma Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045415?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:51","pubTimestamp":1762465878,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc reports results for the quarter ended September 30 - Earnings SummaryaTyr Pharma Inc ATYR.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended September 30","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL8N3WI3TN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2581012792","title":"aTyr Pharma reports third quarter 2025 results and updates on efzofitimod studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012792","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012792?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462902,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. reported cash, cash equivalents, restricted cash, and available-for-sale investments of $92.9 million as of September 30, 2025. Research and development expenses for the third quarter of 2025 were $22.1 million, primarily related to clinical trial and manufacturing costs for the efzofitimod program. General and administrative expenses were $4.8 million for the same period. During the quarter, aTyr Pharma announced results for the Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis and plans to meet with the FDA in the first quarter of 2026 to determine next steps. The company also expects to complete enrollment in the Phase 2 EFZO-CONNECT study in systemic sclerosis-related interstitial lung disease in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sho","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7lDkJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4585","BK4139","LU2095319765.USD","BK4588","LU2210149790.SGD","ATYR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2581201203","title":"Press Release: aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581201203","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581201203?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462860,"startTime":"0","endTime":"0","summary":"Results reported for Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis.Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.\"Based on the findings from EFZO-FIT, we believe there is drug activity for efzofitimod as evidenced by improvements across multiple clinically relevant efficacy measures. Based on this, coupled with the ongoing high unmet medical need in pulmonary sarcoidosis, we plan to meet with the U.S. Food and Drug Administration  in the first quarter of 2026 to review the results of the study and determine the path forward for efzofitimod in pulmonary sarcoidosis. We plan to provide an update regarding the next steps for the program following that meeting.\". Fatigue Assessment Scale, and complete steroid withdrawal and improvement","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4604","ATYR","BK4555","BK4588","BK4585","BK4099","TM","BK4139"],"gpt_icon":0},{"id":"2581811012","title":"aTyr Pharma Inc options imply 21.3% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2581811012","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581811012?lang=en_us&edition=fundamental","pubTime":"2025-11-07 04:35","pubTimestamp":1762461318,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in aTyr Pharma (ATYR) Inc is normal with calls leading puts 3:2. Implied volatility suggests the market is anticipating...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-21-3-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-21-3-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2581065756","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2581065756","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581065756?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:00","pubTimestamp":1762426800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A-Mark Precs Mtl                                1Q       .60    4:05 PM. ·Achve Life Scncs                                3Q      (.24)   7:30 AM. ·Air Pdts and Chem                                4Q      3.38    6:00 AM. ·Alpha Metall Rsrcs                               3Q      (.52)   7:30 AM. ·Altice USA Inc.                                 3Q      (.06)   7:00 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARHS","AMTX","AFRM","ALT","ABCL","APPN","ADV","ACRV","ACIW","AMR","AHR","BIRD","OPTU","ABL","ASMB","ASTH","ATLC","ALRM","AAOI","AMBQ","ALTG","AVAH","AGO","AMRK","ASPN","ATYR","ADVM","BIOA","ATHM","AMLX","AMPH","CARL","APYX","ACHV","APLT","AORT","ATUS","BLZE","AEE","ALG","ARLO","AURA","AMN","ALLO","APD","AAON","AMPX","AKAM","ABNB","GOOS"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.atyrpharma.com","stockEarnings":[{"period":"1week","weight":0.0556},{"period":"1month","weight":0.0124},{"period":"3month","weight":-0.8531},{"period":"6month","weight":-0.8469},{"period":"1year","weight":-0.748},{"period":"ytd","weight":-0.7724}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.026814},{"month":2,"riseRate":0.4,"avgChangeRate":-0.021771},{"month":3,"riseRate":0.4,"avgChangeRate":-0.056841},{"month":4,"riseRate":0.3,"avgChangeRate":-0.032312},{"month":5,"riseRate":0.5,"avgChangeRate":-0.058101},{"month":6,"riseRate":0.545455,"avgChangeRate":-0.018872},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.001577},{"month":8,"riseRate":0.181818,"avgChangeRate":-0.059775},{"month":9,"riseRate":0.454545,"avgChangeRate":0.014241},{"month":10,"riseRate":0.363636,"avgChangeRate":0.029504},{"month":11,"riseRate":0.545455,"avgChangeRate":0.024303},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.056422}],"exchange":"NASDAQ","name":"ATYR PHARMA INC","nameEN":"ATYR PHARMA INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ATYR PHARMA INC,ATYR,ATYR PHARMA INC股票,ATYR PHARMA INC股票老虎,ATYR PHARMA INC股票老虎国际,ATYR PHARMA INC行情,ATYR PHARMA INC股票行情,ATYR PHARMA INC股价,ATYR PHARMA INC股市,ATYR PHARMA INC股票价格,ATYR PHARMA INC股票交易,ATYR PHARMA INC股票购买,ATYR PHARMA INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction